It antagonizes estrogen action by competing for the binding of ER in breast cancer cells and is thought to repress ER-mediated transcriptional activation by actively recruiting co-repressors (Katzenellenbogen and Frasor 2004; Malik et al. 2010; Hurtado et al. 2011). Here, ESR1 is linked to breast cancer.